Revance Therapeutics targets positive adjusted EBITDA by 2025, banking on new product launches like RHA Dynamic Volume and practitioner training to drive growth in the aesthetics market.

"This study marks the U.S. introduction of a midface contouring approach that has been supported by more than a decade of post-marketing surveillance in Europe," states Sandra Chennoufi, Chief ...

Teoxane today announced the publication in the Aesthetic Surgery Journal of a pivotal randomized, controlled, double-blinded trial evaluating the safety and effectiveness of RHA® 3 for lip ...

It’s common to encounter different filler products when visiting various facial plastic surgeons, dermatologists or med spas. familylifestyle/iStock / Getty Images Plus Q. I’ve gone to several ...

Dr. Carlos Wolf is a partner at Miami Plastic Surgery and is board certified. In this edition of our Q&A column, a patient writes to Dr. Wolf expressing some confusion about the wide variety of facial ...

According to the terms of the deal, Crown will buy Revance at $3.65 per share At the closing, Revance will no longer trade on the Nasdaq Revance’s portfolio includes Daxxify for injection and the RHA ...

I initially downgraded Revance Therapeutics to a "Sell" in June due to financial struggles, competition, and potential cash flow issues by 2025. Revance's merger with Crown Labs at $6.66 per share, an ...

Crown Laboratories, a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, a biotechnology with aesthetic and therapeutic offerings, have entered into a merger ...

Revance Therapeutics, Inc. operates in the aesthetics and therapeutics markets, selling Daxxify and RHA Collection of dermal fillers in the U.S. Despite positive guidance for 2024, the Revance stock ...